NewsDiseasesSymptomsInjuriesDrugsProceduresToolsSelf-care








HER2 Inhibitors News
Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
Dove Press - Monday, November 13, 2023
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Nature - Saturday, November 11, 2017




  Subtypes


Related Drugs:

Web

  • Breast Cancer Therapeutics Market to be Dominated by HER2 Inhibitors - Transparency Market Research.
  • http://www.thefreelibrary.com/Breast+Cancer+Therapeutics+Market+t...
  • HER2 inhibitors was the largest segment of the global breast cancer therapeutics market in 2014.
    		•
  • Breast Cancer Therapy : Right On Target
  • http://www.drugs.com/slideshow/breast-cancer-therapy-right-on-tar...
  • HER2 inhibitors often have more mild side effects than traditional chemotherapy.
    		•
  • Bayesian network meta-analysis, comparison of cardiac events associated with liposomal doxorubicin, epirubicin, and doxorubicin in breast cancer. ; 2014 ASCO Annual Meeting
  • http://meetinglibrary.asco.org/content/129584-144
  • We included studies published up to January 1, 2014, adjuvant and metastatic regimens, but not HER2/neu inhibitor containing regimens.
    		•
  • Cancer Ouija Boards, Umbrellas, and Baskets : The Evolution of Genomic Oncology
  • http://cancergrace.org/cancer-101/2014/11/02/cancer-ouija-boards-...
  • For instance, a trial with a novel HER2 inhibitor might be opened for patient with a HER2 abnormality whether they have breast cancer, gastric cancer, lung cancer, or any other type of cancer.
    		•
  • Nutrition and Cancer via MedWorm.com ; In Memoriam : UNMC Cancer Researcher, Dr. Sidney Mirvish, 1929-2015.
  • http://www.medworm.com/rss/medicalfeeds/source/Nutrition+and+Canc...
  • OOS reduced the proliferation of these cells, and augmented the action of lapatinib, a HER2 inhibitor used i...
  • Oncothyreon Inc And Array BioPharma Inc Announce Initiation Of Phase 1b Trial Of ONT 380 In Combination With Capecitabine And Or Trastuzumab In Patients
  • http://www.biospace.com/News/oncothyreon-inc-and-array-biopharma-...
  • "We believe the unique pharmacologic properties of ONT-380, as the only oral, selective HER2 inhibitor, position it favorably as a potential new option for patients fighting breast cancer."
  • Class of breast cancer drugs could treat other types of cancer - insciences
  • http://insciences.org/article.php?article_id=10527
  • This suggests that treatment with HER2 inhibitors could be beneficial in patients even if they only had low levels of the protein.
    		•
  • Breast Cancer SPORE
  • http://www.med.unc.edu/radonc/proj/breast-cancer-spore
  • LCCC0411: This trial follows on Dr. Sartor's laboratory studies of the EGFR/HER2 inhibitor, lapatinib (Tykerb), that indicate that lapatinib may be an effective radiosensitizer for locally advanced breast cancer.
    		•
  • Evaluation of chromosome 17 (Chr-17) polysomy in Her2 FISH-negative metastatic breast cancer (MBC)
  • http://www.oncolink.org/conferences/article.cfm?c=3&s=48&ss=268&i...
  • Previous studies have suggested that chromosome 17 polysomy may cause an increase in Her-2 gene expression, which may be associated with a benefit in patients treated with Her2 inhibitors, such as lapatinib.
  • Medical Management of Chordomas ; Memorial Sloan Kettering Cancer Center
  • https://www.mskcc.org/clinical-updates/medical-management-chordomas
  • A phase II study of a novel HER2 inhibitor is underway and might be considered for patients with chordoma, given the high expression of HER2 and EGFR with this neoplasm. (Please note that this trial is closed to accrual.)
    • 1 2 3 4 5 6 7 8 9 ⇨

    News

    Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers
    Dove Press - Monday, November 13, 2023
    BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
    Nature - Saturday, November 11, 2017

    Videos

    Adjuvant Treatment, HER2 Positive & Targeted Therapies
           
    William Gradishar, MD, Director at the Maggie Daley Center for Womens Cancer Care, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
    BOLERO-1 reports HER2-positive breast cancer latest PFS data
           
    Visit http://www.ecancer.org for more. Prof Hurvitz (University of California, Los Angeles, USA) talks to ecancertv at SABCS 2014 about the results of a phase III trial which looked at the effects of daily everolimus plus weekly trastuzumab and paclita...
    Patients with Lung Cancer Harboring a Rare HER2 Alteration May Benefit from anti-HER2 Therapy ; Cancer.Net
           
    Patients with Lung Cancer Harboring a Rare HER2 Alteration May Benefit from anti-HER2 Therapy ; Cancer.Net
    Mayo Clinic: Combining a Targeted Drug with Chemotherapy Offers Longer Life to Patients with B-Cell Cancers
           
    Master "Cut-off Switch" for Cancer-Causing HER2 Protein Located
    Edith A. Perez, MD: Anti-HER2 Therapies
           
    Dr. Edith Perez sits down with Selma Schimmel and The Group Room at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). They discuss her recent research with Anti-HER2 therapies presented at SABCS 2012. Edith A. Perez, MD is Deputy ...
    Extended adjuvant therapy for HER2-positive early breast cancer
           
    Visit http://www.ecancer.org for more Prof Chan (The Mount Hospital, Perth, Australia) talks to ecancertv at ASCO 2015, discusses adjuvant targeted therapy for HER2-positive early breast cancer, evaluating the effects of neratinib after adjuvant trastu...
    ASCO 2013 - Debu Tripathy - HER2 Targeted Therapies
           
    Debu Tripathy, MD, CURE Magazine's Editor-in-Chief, talks about HER2 targeted therapies that were presented at the 2013 American Society of Clinical Oncology meeting in Chicago, Il.
    HER2 Positive Metastatic Breast Cancer Advances
           
    Edith A. Perez, MD, Director, Clinical Investigation and Breast Cancer Program, Division of Hematology and Oncology, The Mayo Clinic, Jacksonville, Florida.
    Comment: BOLERO-1 reports HER2-positive breast cancer latest PFS data
           
    Visit http://www.ecancer.org for more. Prof Osborne (Baylor College of Medicine, Houston, USA) provides his expert opinion to ecancertv on data presented by Prof Hurvitz at SABCS 2014 about the effects of daily everolimus plus weekly trastuzumab and pa...
    AACR 2011: New Phase I targeted cancer drugs.
           
    Dr Lori Friedman - Genentech, California, USA Dr Lori Friedman, director of cancer signalling and translational oncology at Genentech, speaks about a session at the 2011 AACR congress where a number of previously undisclosed drugs in Stage I clinical t...
    1 2 3 4 5 6 7 8 9 ⇨

    Images

    Immune Checkpoint Inhibitor (CTLA-4)
    Immune Checkpoint Inhibitor (PD-1)
    An enzyme binding site that would normally bind substrate can alternatively bind a competitive inhibitor, preventing substrate access.
    fraction of the enzyme population bound by inhibitor
    the effect of the inhibitor is a result of the percent of the enzyme population interacting with inhibitor.
    Immune Checkpoint Inhibitor (CTLA-4)
    cancer.gov    		 Immune Checkpoint Inhibitor (PD-1)
    cancer.gov    		 An enzyme binding site that would normally bind substrate can alternatively bind a competitive inhibitor, preventing substrate access.
    en.wikipedia.org    		 fraction of the enzyme population bound by inhibitor
    en.wikipedia.org    		 the effect of the inhibitor is a result of the percent of the enzyme population interacting with inhibitor.
    en.wikipedia.org
    1xan: HUMAN GLUTATHIONE REDUCTASE IN COMPLEX WITH A XANTHENE INHIBITOR
    1bwc: STRUCTURE OF HUMAN GLUTATHIONE REDUCTASE COMPLEXED with AJOENE INHIBITOR AND SUBVERSIVE SUBSTRATE
    Captopril, the first synthetic ACE inhibitor
    Blister pack of Prozac (fluoxetine), a selective serotonin reuptake inhibitor
    1gag: CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
    1xan: HUMAN GLUTATHIONE REDUCTASE IN COMPLEX WITH A XANTHENE INHIBITOR
    en.wikipedia.org    		 1bwc: STRUCTURE OF HUMAN GLUTATHIONE REDUCTASE COMPLEXED with AJOENE INHIBITOR AND SUBVERSIVE SUBSTRATE
    en.wikipedia.org    		 Captopril, the first synthetic ACE inhibitor
    en.wikipedia.org    		 Blister pack of Prozac (fluoxetine), a selective serotonin reuptake inhibitor
    en.wikipedia.org    		 1gag: CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
    en.wikipedia.org
    350px Simvastatin Structural Formulae
    2e1w: Crystal structure of adenosine deaminase complexed with potent inhibitors
    1wxz: Crystal structure of adenosine deaminase ligated with a potent inhibitor
    1wxy: Crystal structure of adenosine deaminase ligated with a potent inhibitor
    1v7a: Crystal structures of adenosine deaminase complexed with potent inhibitors
    350px Simvastatin Structural Formulae
    en.wikipedia.org    		 2e1w: Crystal structure of adenosine deaminase complexed with potent inhibitors
    en.wikipedia.org    		 1wxz: Crystal structure of adenosine deaminase ligated with a potent inhibitor
    en.wikipedia.org    		 1wxy: Crystal structure of adenosine deaminase ligated with a potent inhibitor
    en.wikipedia.org    		 1v7a: Crystal structures of adenosine deaminase complexed with potent inhibitors
    en.wikipedia.org
    1v79: Crystal structures of adenosine deaminase complexed with potent inhibitors
    1uml: Crystal structure of adenosine deaminase complexed with a potent inhibitor FR233624
    1o5r: Crystal structure of adenosine deaminase complexed with a potent inhibitor
    6pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND L-DOPA (3,4-DIHYDROXYPHENYLALANINE) INHIBITOR
    5pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND DOPAMINE INHIBITOR
    1v79: Crystal structures of adenosine deaminase complexed with potent inhibitors
    en.wikipedia.org    		 1uml: Crystal structure of adenosine deaminase complexed with a potent inhibitor FR233624
    en.wikipedia.org    		 1o5r: Crystal structure of adenosine deaminase complexed with a potent inhibitor
    en.wikipedia.org    		 6pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND L-DOPA (3,4-DIHYDROXYPHENYLALANINE) INHIBITOR
    en.wikipedia.org    		 5pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND DOPAMINE INHIBITOR
    en.wikipedia.org
    4pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND NOR-ADRENALINE INHIBITOR
    3pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND ADRENALINE INHIBITOR
    Her2 and Her3 distribution on a breast cell, (3D Dual Colour Super Resolution Microscopy SPDMphymod / LIMON,marked with Alexa 488 and 568)
    250px Trastuzumab Fab HER2 complex 1N8Z
    1n8z: Crystal structure of extracellular domain of human HER2 complexed with Herceptin Fab
    4pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND NOR-ADRENALINE INHIBITOR
    en.wikipedia.org    		 3pah: HUMAN PHENYLALANINE HYDROXYLASE CATALYTIC DOMAIN DIMER WITH BOUND ADRENALINE INHIBITOR
    en.wikipedia.org    		 Her2 and Her3 distribution on a breast cell, (3D Dual Colour Super Resolution Microscopy SPDMphymod / LIMON,marked with Alexa 488 and 568)
    en.wikipedia.org    		 250px Trastuzumab Fab HER2 complex 1N8Z
    en.wikipedia.org    		 1n8z: Crystal structure of extracellular domain of human HER2 complexed with Herceptin Fab
    en.wikipedia.org
    800px Renin inhibitor timeline
    Crystal structure of acetoacetate decarboxylase in complex with an inhibitor, pentan-2-one.
    Aliskiren,[1] the first renin inhibitor to be marketed
    The structure of human thrombin in complex with the inhibitor hirudin.[1]
    Remikiren, a second-generation renin inhibitor
    800px Renin inhibitor timeline
    en.wikipedia.org    		 Crystal structure of acetoacetate decarboxylase in complex with an inhibitor, pentan-2-one.
    en.wikipedia.org    		 Aliskiren,[1] the first renin inhibitor to be marketed
    en.wikipedia.org    		 The structure of human thrombin in complex with the inhibitor hirudin.[1]
    en.wikipedia.org    		 Remikiren, a second-generation renin inhibitor
    en.wikipedia.org
    1ad8: COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY
    Aliskiren, the third-generation renin inhibitor
    1a61: THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR
    1ad8: COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY
    en.wikipedia.org    		 Aliskiren, the third-generation renin inhibitor
    en.wikipedia.org    		 1a61: THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR
    en.wikipedia.org
    MORE IMAGES

    About Seenso | Mission Statement | Disclosure | Privacy | Policy Disclaimers | Terms and Conditions | Contact Us | | |